Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Serum MMP-10 levels predict incident inflammatory bowel disease: an observational analysis from the PURE study.

Created on 15 Nov 2026

Authors

Emily C L Wong, Walter Reinisch, Paul Moayyedi, Sumathy Rangarajan, Philip Joseph, Paul Poirier, Scott Lear, Maria Luz Diaz, Roya Kelishadi, Alvaro Avezum, Patricio Lopez-Jaramillo, Annika Rosengren, Fernando Lanas, Iolanthé M Kruger, Rita Yusuf, Afzalhussein Yusufali, Marc Evans Abat, Jephat Chifamba, Karen Yeates, Romaina Iqbal, Nicolas Perrot, Nicole H Chang, Guillaume Paré, Neeraj Narula

Published in

Journal of Crohn's & colitis. Volume 20. Issue 11. Nov 07, 2026.

Abstract

The incidence of inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is rising, particularly in middle-income countries. This study aims to identify biomarkers that predict the onset of IBD in a globally recruited population.
Data from participants enrolled in the biomarker substudy of the Prospective Urban Rural Epidemiology (PURE) study were analyzed (discovery cohort). The primary outcome of interest was the development of incident IBD. Secondary outcomes were CD and UC. Protein concentration was measured using O-link® immuno-assays. Discovery analyses consisted of logistic regression models to evaluate the relationship between biomarker concentrations and risk of IBD. A separate analysis was conducted to validate biomarkers identified from the discovery cohort. Statistical significance was defined using a Bonferroni-corrected P < 1.6 × 10-5 for all analyses.
A total of 1011 biomarkers were assessed in the discovery cohort across 11 019 participants with n = 91 incident IBD cases. In the discovery analysis, elevated levels of matrix metalloproteinase-10 (MMP-10) were significantly associated with a future diagnosis of IBD (adjusted odds ratio [aOR] per SD: 1.75, 95% confidence interval [CI]: 1.40-2.18, P = 7.6 × 10-7). Results were consistent in direction for development of both UC and CD. In the validation analysis, MMP-10 remained significant for the outcome of IBD (aOR per SD: 2.41 [95% CI: 1.61-4.58], P = 5.2 × 10-6).
These findings suggest MMP-10 is a relevant biomarker in the general global population for prediction of clinical IBD, and further work should investigate its role in early detection and prevention strategies.

PMID:
43034053
Bibliographic data and abstract were imported from PubMed on 15 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 13
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement